Israel - English - Ministry of Health

novartis israel ltd - aripiprazole - tablets - aripiprazole 30 mg - aripiprazole - aripiprazole sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment

Israel - English - Ministry of Health

novartis israel ltd - aripiprazole - tablets - aripiprazole 30 mg - aripiprazole - aripiprazole sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment

Israel - English - Ministry of Health

novartis israel ltd - aripiprazole - tablets - aripiprazole 5 mg - aripiprazole - aripiprazole sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (mdd). efficacy was established in two 6-week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode.aripiprazole sandoz is indicated for the treatment of irritability associated with autistic disorder. efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).

Israel - English - Ministry of Health

novartis israel ltd - aripiprazole - tablets - aripiprazole 5 mg - aripiprazole - aripiprazole sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (mdd). efficacy was established in two 6-week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode.aripiprazole sandoz is indicated for the treatment of irritability associated with autistic disorder. efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - aripiprazole - tablet - 10 milligram(s) - other antipsychotics; aripiprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - aripiprazole - tablet - 15 milligram(s) - other antipsychotics; aripiprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - aripiprazole - tablet - 30 milligram(s) - other antipsychotics; aripiprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - aripiprazole - tablet - 5 milligram(s) - other antipsychotics; aripiprazole

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: tartaric acid; microcrystalline cellulose; croscarmellose sodium; iron oxide red; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.